257 related articles for article (PubMed ID: 33028675)
1. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib.
Kay J; Harigai M; Rancourt J; Dickson C; Melby T; Issa M; de la Torre I; Isaka Y; Cardoso A; Saifan C; Keystone EC; van Vollenhoven RF; Giles JT; Huizinga TW; Kremer JM
RMD Open; 2020 Oct; 6(3):. PubMed ID: 33028675
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Smolen JS; Genovese MC; Takeuchi T; Hyslop DL; Macias WL; Rooney T; Chen L; Dickson CL; Riddle Camp J; Cardillo TE; Ishii T; Winthrop KL
J Rheumatol; 2019 Jan; 46(1):7-18. PubMed ID: 30219772
[TBL] [Abstract][Full Text] [Related]
4. Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.
Tanaka Y; McInnes IB; Taylor PC; Byers NL; Chen L; de Bono S; Issa M; Macias WL; Rogai V; Rooney TP; Schlichting DE; Zuckerman SH; Emery P
Arthritis Rheumatol; 2018 Dec; 70(12):1923-1932. PubMed ID: 30058112
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
Keystone EC; Taylor PC; Drescher E; Schlichting DE; Beattie SD; Berclaz PY; Lee CH; Fidelus-Gort RK; Luchi ME; Rooney TP; Macias WL; Genovese MC
Ann Rheum Dis; 2015 Feb; 74(2):333-40. PubMed ID: 25431052
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
7. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Winthrop KL; Harigai M; Genovese MC; Lindsey S; Takeuchi T; Fleischmann R; Bradley JD; Byers NL; Hyslop DL; Issa M; Nishikawa A; Rooney TP; Witt S; Dickson CL; Smolen JS; Dougados M
Ann Rheum Dis; 2020 Oct; 79(10):1290-1297. PubMed ID: 32788396
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
[TBL] [Abstract][Full Text] [Related]
9. The safety of baricitinib in patients with rheumatoid arthritis.
Honda S; Harigai M
Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Qiu C; Zhao X; She L; Shi Z; Deng Z; Tan L; Tu X; Jiang S; Tang B
Lipids Health Dis; 2019 Feb; 18(1):54. PubMed ID: 30777075
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
[TBL] [Abstract][Full Text] [Related]
13. The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
Thudium CS; Bay-Jensen AC; Cahya S; Dow ER; Karsdal MA; Koch AE; Zhang W; Benschop RJ
Arthritis Res Ther; 2020 Oct; 22(1):235. PubMed ID: 33046136
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib.
Anjara P; Jiang M; Mundae M
Clin Rheumatol; 2020 Feb; 39(2):613-614. PubMed ID: 31782014
[TBL] [Abstract][Full Text] [Related]
15. Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis.
Dabal TD; Haltom MB; Patel PP; Son CK; Joglekar KP; Groeschell CM; Chumpia MM; Kamal SF; Seth A; Jackson CD
South Med J; 2021 May; 114(5):288-292. PubMed ID: 33942113
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
Emery P; Durez P; Hueber AJ; de la Torre I; Larsson E; Holzkämper T; Tanaka Y
Arthritis Res Ther; 2021 Jan; 23(1):3. PubMed ID: 33397481
[TBL] [Abstract][Full Text] [Related]
17. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
Li ZG; Hu JK; Li XP; Yang Y; Li XF; Xu JH; Zhang X; Xu J; Bao CD; He DY; Li ZJ; Wang GC; Zuo XX; Liu Y; Xiao ZY; Chen JW; Xin XF; Li JY; Jiang LD; Liu MR; Ji F; Li CG
Adv Ther; 2021 Jan; 38(1):772-781. PubMed ID: 33237533
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
Li Z; Hu J; Bao C; Li X; Li X; Xu J; Spindler AJ; Zhang X; Xu J; He D; Li Z; Wang G; Yang Y; Wu H; Ji F; Tao H; Zhan L; Bai F; Rooney TP; Zerbini CAF
Clin Exp Rheumatol; 2020; 38(4):732-741. PubMed ID: 32452344
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Taylor PC; Weinblatt ME; Burmester GR; Rooney TP; Witt S; Walls CD; Issa M; Salinas CA; Saifan C; Zhang X; Cardoso A; González-Gay MA; Takeuchi T
Arthritis Rheumatol; 2019 Jul; 71(7):1042-1055. PubMed ID: 30663869
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.
Tanaka Y; Ishii T; Cai Z; Schlichting D; Rooney T; Macias W
Mod Rheumatol; 2018 Jan; 28(1):20-29. PubMed ID: 28440680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
